Germany's Merck and GlaxoSmithKline have announced a global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult to treat cancers, in a deal worth up to 3.7 billion euros.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.